Arrowhead Pharmaceuticals Financial Statements (ARWR)
|
|
|
|
Report date
|
|
|
25.11.2019 |
23.11.2020 |
22.11.2021 |
28.11.2022 |
29.11.2023 |
|
08.08.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
168.8 |
88.0 |
138.3 |
243.2 |
240.7 |
|
19.6 |
|
Operating Income, bln rub |
|
|
61.2 |
-93.2 |
-149.0 |
-178.5 |
-205.0 |
|
-547.2 |
|
EBITDA, bln rub |
? |
|
65.6 |
-87.2 |
-132.6 |
-162.3 |
-175.7 |
|
-508.3 |
|
Net profit, bln rub |
? |
|
68.0 |
-84.6 |
-140.8 |
-176.5 |
-205.3 |
|
-538.6 |
|
|
OCF, bln rub |
? |
|
173.0 |
-95.4 |
171.2 |
-136.1 |
-153.9 |
|
-350.9 |
|
CAPEX, bln rub |
? |
|
12.0 |
12.0 |
23.6 |
52.8 |
176.7 |
|
181.1 |
|
FCF, bln rub |
? |
|
161.0 |
-107.3 |
147.7 |
-188.9 |
-330.6 |
|
-532.0 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
107.6 |
181.2 |
287.3 |
421.7 |
445.7 |
|
562.3 |
|
Cost of production, bln rub |
|
|
0.000 |
0.000 |
0.000 |
10.4 |
0.000 |
|
17.4 |
|
R&D, bln rub |
|
|
81.0 |
128.9 |
206.3 |
297.3 |
353.2 |
|
465.8 |
|
Interest expenses, bln rub |
|
|
6 958 |
9 191 |
6.12 |
5.03 |
18.3 |
|
23.0 |
|
|
Assets, bln rub |
|
|
349.8 |
522.5 |
710.1 |
691.9 |
765.6 |
|
883.8 |
|
Net Assets, bln rub |
? |
|
244.6 |
461.8 |
408.8 |
106.0 |
271.3 |
|
330.5 |
|
Debt, bln rub |
|
|
0.000 |
21.1 |
25.5 |
81.6 |
115.2 |
|
454.1 |
|
Cash, bln rub |
|
|
258.7 |
315.5 |
367.8 |
376.4 |
403.6 |
|
436.7 |
|
Net debt, bln rub |
|
|
-258.7 |
-294.4 |
-342.2 |
-294.8 |
-288.5 |
|
17.5 |
|
|
Ordinary share price, rub |
|
|
28.2 |
43.1 |
62.4 |
33.1 |
26.9 |
|
26.2 |
|
Number of ordinary shares, mln |
|
|
93.9 |
100.7 |
103.7 |
105.4 |
107.3 |
|
124.2 |
|
|
Market cap, bln rub |
|
|
2 645 |
4 337 |
6 477 |
3 484 |
2 883 |
|
3 249 |
|
EV, bln rub |
? |
|
2 386 |
4 043 |
6 135 |
3 190 |
2 595 |
|
3 266 |
|
Book value, bln rub |
|
|
228 |
446 |
395 |
94 |
261 |
|
322 |
|
|
EPS, rub |
? |
|
0.72 |
-0.84 |
-1.36 |
-1.67 |
-1.91 |
|
-4.34 |
|
FCF/share, rub |
|
|
1.72 |
-1.07 |
1.42 |
-1.79 |
-3.08 |
|
-4.28 |
|
BV/share, rub |
|
|
2.42 |
4.43 |
3.81 |
0.89 |
2.43 |
|
2.59 |
|
|
EBITDA margin, % |
? |
|
38.9% |
-99.1% |
-95.9% |
-66.7% |
-73.0% |
|
-2 587% |
|
Net margin, % |
? |
|
40.3% |
-96.1% |
-101.9% |
-72.6% |
-85.3% |
|
-2 741% |
|
FCF yield, % |
? |
|
6.09% |
-2.48% |
2.28% |
-5.42% |
-11.5% |
|
-16.4% |
|
ROE, % |
? |
|
27.8% |
-18.3% |
-34.5% |
-166.6% |
-75.7% |
|
-163.0% |
|
ROA, % |
? |
|
19.4% |
-16.2% |
-19.8% |
-25.5% |
-26.8% |
|
-60.9% |
|
|
P/E |
? |
|
38.9 |
-51.3 |
-46.0 |
-19.7 |
-14.0 |
|
-6.03 |
|
P/FCF |
|
|
16.4 |
-40.4 |
43.9 |
-18.4 |
-8.72 |
|
-6.11 |
|
P/S |
? |
|
15.7 |
49.3 |
46.8 |
14.3 |
12.0 |
|
165.4 |
|
P/BV |
? |
|
11.6 |
9.72 |
16.4 |
37.1 |
11.0 |
|
10.1 |
|
EV/EBITDA |
? |
|
36.4 |
-46.4 |
-46.3 |
-19.7 |
-14.8 |
|
-6.43 |
|
Debt/EBITDA |
|
|
-3.94 |
3.37 |
2.58 |
1.82 |
1.64 |
|
-0.03 |
|
|
R&D/CAPEX, % |
|
|
675.3% |
1 078% |
875.6% |
563.3% |
199.8% |
|
257.2% |
|
|
CAPEX/Revenue, % |
|
|
7.11% |
13.6% |
17.0% |
21.7% |
73.4% |
|
921.7% |
|
| Arrowhead Pharmaceuticals shareholders |
